

# Regimen Reference Order – BRST – palbociclib + letrozole

## ARIA: BRST – [palbociclib + letrozole]

**Planned Course:** Until disease progression or unacceptable toxicity (1 cycle = 28 days)

**Indication for Use:** Breast Cancer Metastatic

***Proceed with treatment if:***

***ANC equal to or greater than  $1 \times 10^9/L$  AND Platelets equal to or greater than  $75 \times 10^9/L$***

***❖ Contact Physician if parameters not met***

### SEQUENCE OF MEDICATION ADMINISTRATION

#### Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

#### Treatment Regimen – BRST – palbociclib + letrozole

Drug	Dose	CCMB Administration Guideline
letrozole	2.5 mg	Orally daily on <b>Days 1 to 28</b> . Continued regardless of blood counts Take with or without food <b>(Self-administered at home)</b>
palbociclib	125 mg	Orally daily on <b>Days 1 to 21, then 7 days off</b> Take with food <b>(Self-administered at home)</b>
<p><b>letrozole (Femara®) available dosage strength: 2.5 mg tablet</b>  <b>Classification: Non-Cytotoxic, Hazardous</b></p> <p><b>palbociclib (Ibrance®) available dosage strengths: 75 mg; 100 mg; 125 mg capsules</b>  <b>Classification: Non-Cytotoxic, Hazardous</b></p>		

### REQUIRED MONITORING

**Baseline**

- CBC, biochemistry as per physician order

**Cycles 1 and 2**

- CBC prior to Days 1 and 15

**Cycles 3 to 6**

- CBC prior to Day 1 and as clinically indicated

**Cycles 7 and onwards**

- CBC prior to Day 1 as per physician’s discretion
- Every 3<sup>rd</sup> cycle if ANC was  $1 \times 10^9/L$  or greater during first 6 cycles
- Prior to each cycle if ANC was less than  $1 \times 10^9/L$  during first 6 cycles

**Throughout therapy**

- LFTs and renal function as clinically indicated
- Clinical toxicity assessment at each visit (infection, bleeding, thrombocytopenia, rash, headache, mucositis, fatigue, GI effects)

### Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
Not Applicable		

### INSTRUCTIONS FOR PATIENT

- letrozole has potential for drug-drug interactions. Patients should notify clinic prior to starting any new medication
- palbociclib has potential for drug-drug interactions. Patients should notify clinic prior to starting any new medication
- Avoid grapefruit or grapefruit juice with palbociclib

### ADDITIONAL INFORMATION

- letrozole may be substituted with anastrozole 1mg orally once daily OR exemestane 25mg orally once daily at the physician's discretion
- palbociclib will be dispensed by CancerCare Manitoba Pharmacy
- If there are any dose interruptions with palbociclib, the aromatase inhibitor (letrozole, anastrozole, or exemestane) continue to be taken by patient on a daily basis

The recommended dose adjustments for hematological parameters:

Absolute Neutrophil Count (ANC)	palbociclib dose
Equal to or greater than $1 \times 10^9/L$	Continue same dose
ANC between $0.5 \times 10^9/L$ and $1 \times 10^9/L$	<p><u>Day 1 of cycle:</u> Hold. If ANC <math>1 \times 10^9/L</math> or higher within 1 week, resume at same dose</p> <p><u>Day 15 of cycles 1 and 2:</u> Continue same dose and repeat CBC on day 22.</p> <p>If ANC on Day 22 is:  <math>1 \times 10^9/L</math> or higher: Repeat CBC prior to the next cycle and resume at same dose if ANC equal to or greater than <math>1 \times 10^9/L</math></p> <p><math>0.5 \times 10^9/L</math> to less than <math>1 \times 10^9/L</math>: Repeat CBC prior to the next cycle and resume at next lower dose when ANC is <math>1 \times 10^9/L</math> or higher</p>
ANC less than $0.5 \times 10^9/L$ OR ANC between $0.5 \times 10^9/L$ and $1 \times 10^9/L$ plus fever and/or infection	Hold. When ANC is $1 \times 10^9/L$ or higher, resume at next lower dose